Taskin Omur, Muderrisoglu Haldun, Akar Munire, Simsek Mehmet, Mendilcioglu Inanc, Kursun Sinan
Department of Obstetrics/Gynecology, Division of Reprod. Endoc., Akdeniz University School of Medicine, Antalya, Turkey.
Maturitas. 2004 Aug 20;48(4):354-9. doi: 10.1016/j.maturitas.2003.08.014.
This study is designed to investigate and compare the effects of synthetic steroid tibolone and HRT on systolic and diastolic heart functions in post-menopausal women.
This prospective, randomized placebo controlled double blind study was conducted in a university clinic. Fifty-eight non-smoking, otherwise healthy post-menopausal women who did not receive any kind of HRT at least for 3 years within the onset of menopause were included in the study. The patients were randomly allocated to either 2.5 mg per day tibolone (OD, n = 18), daily combined 0.625 mg of conjugated estrogens 2.5 mg-1 of medroxy progesterone acetate pill (EP, n = 20) or a vitamin pill (n= 20) in a double blinded fashion. Their basic systolic and diastolic functions were investigated with HP Sonos-1000 echocardiography using standard positions and windows before and 6 months after the initiation of HRT.
Mean age, weight, length of post-menopausal period, heart rate, systolic and diastolic pressures were similar between the groups. At the initiation of the study all groups had similar echocardiographic measurements. However, at the end of 6 months, left ventricular end-systolic and -diastolic volumes were decreased significantly compared to pretreatment and placebo in both EP and OD treated groups. (55.5 +/- 18.4 and 53.7 +/- 19.1.8 ml; 109.9 +/-19.9 and 110.7 +/- 20.8 ml versus 74.5 +/- 14.9 and 142.7 +/- 19.1 ml, respectively; P < 0.05). Improvement in diastolic functions was significant in EP/OD groups compared to pre-treatment period and the placebo groups (E/A 1.34 +/- 0.1 and 1.38 +/- 0.1 versus 1.18 +/-.09, deceleration time 204 +/- 11.1 and 202.8 +/- 27.1 ms versus 237.6 +/- 26.9 ms, respectively). Besides increase in left ventricular mass adjusted for height, decrease in left ventricular relative wall thickness, and systemic vascular resistance were significant in EP and OD treated groups than placebo and the pre-treatment measurements. Although improved in both OD and EP groups, the changes in systolic and diastolic functions were significantly higher in the OD treated group. Based on our preliminary results, we may conclude that both EP and OD regimens may improve cardiac performance and age related dysfunctions.
The present results may further support that both OD and EP exert many direct effects on cardiovascular system other than metabolic changes regarding lipoproteins. The greater improvement in the OD group may be explained by its weak androgenic activity which is consistent with the in vitro data that androgens are potent relaxing agents on coronary arteries and restores cardiac myosin isoenzyme and ATPase patterns which mandates further clinical studies.
本研究旨在调查并比较合成类固醇替勃龙和激素替代疗法(HRT)对绝经后女性心脏收缩和舒张功能的影响。
本前瞻性、随机、安慰剂对照双盲研究在一家大学诊所进行。纳入了58名不吸烟、其他方面健康的绝经后女性,她们在绝经开始后至少3年内未接受过任何形式的HRT。患者被随机分为每日服用2.5毫克替勃龙组(OD,n = 18)、每日服用0.625毫克结合雌激素与2.5毫克醋酸甲羟孕酮复方片剂组(EP,n = 20)或维生素片组(n = 20),采用双盲方式。在开始HRT前及开始后6个月,使用HP Sonos - 1000超声心动图,通过标准体位和窗口对她们的基础心脏收缩和舒张功能进行研究。
各组之间的平均年龄、体重、绝经后时长、心率、收缩压和舒张压相似。研究开始时,所有组的超声心动图测量结果相似。然而,在6个月末,与治疗前和安慰剂组相比,EP组和OD组的左心室收缩末期和舒张末期容积均显著降低。(分别为55.5±18.4和53.7±19.1.8毫升;109.9±19.9和110.7±20.8毫升,而安慰剂组为74.5±14.9和142.7±19.1毫升;P < 0.05)。与治疗前期和安慰剂组相比,EP/OD组的舒张功能改善显著(E/A分别为1.34±0.1和1.38±0.1,而治疗前期为1.18±0.09,减速时间分别为204±11.1和202.8±27.1毫秒,而治疗前期为237.6±26.9毫秒)。此外,与安慰剂组和治疗前测量结果相比,EP组和OD组经身高校正后的左心室质量增加、左心室相对壁厚减小以及全身血管阻力降低均显著。虽然OD组和EP组均有改善,但OD治疗组的心脏收缩和舒张功能变化显著更高。基于我们的初步结果,我们可以得出结论,EP和OD方案均可改善心脏功能及与年龄相关的功能障碍。
目前的结果可能进一步支持,OD和EP除了对脂蛋白有代谢改变外,还对心血管系统有许多直接影响。OD组改善更明显可能是由于其弱雄激素活性,这与体外数据一致,即雄激素是冠状动脉的有效舒张剂,并能恢复心肌肌球蛋白同工酶和ATP酶模式,这需要进一步的临床研究。